Follow
Vakaramoko Diaby
Vakaramoko Diaby
Assistant Professor
Verified email at ufl.edu
Title
Cited by
Cited by
Year
Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis
V Diaby, K Campbell, R Goeree
Operations Research for Health Care 2 (1-2), 20-24, 2013
2012013
Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis
G Adunlin, V Diaby, H Xiao
Health Expectations 18 (6), 1894-1905, 2015
1772015
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer
V Diaby, R Tawk, V Sanogo, H Xiao, AJ Montero
Breast cancer research and treatment 151 (1), 27-40, 2015
1142015
How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide
V Diaby, R Goeree
Expert review of pharmacoeconomics & outcomes research 14 (1), 81-99, 2014
1022014
Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward
R Baltussen, K Marsh, P Thokala, V Diaby, H Castro, I Cleemput, M Garau, ...
Value in Health 22 (11), 1283-1288, 2019
832019
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial
V Diaby, G Adunlin, AJ Montero
Pharmacoeconomics 32 (2), 101-108, 2014
742014
Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective
C Tannenbaum, V Diaby, D Singh, S Perreault, M Luc, HM Vasiliadis
Drugs & aging 32 (4), 305-314, 2015
602015
Multicriteria decision analysis in oncology
G Adunlin, V Diaby, AJ Montero, H Xiao
Health Expectations 18 (6), 1812-1826, 2015
442015
Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?
R Goeree, V Diaby
Best practice & research Clinical gastroenterology 27 (6), 831-844, 2013
442013
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States
V Diaby, G Adunlin, AA Ali, SB Zeichner, G de Lima Lopes, CG Kohn, ...
Breast cancer research and treatment 160 (1), 187-196, 2016
332016
Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion
V Diaby, R Goeree, J Hoch, U Siebert
Expert review of pharmacoeconomics & outcomes research 15 (1), 13-19, 2015
292015
Preventing unnecessary costs of drug-induced hypoglycemia in older adults with type 2 diabetes in the United States and Canada
M Boulin, V Diaby, C Tannenbaum
PloS one 11 (9), e0162951, 2016
272016
An application of a proposed framework for formulary listing in low-income countries
V Diaby, J Lachaine
Applied health economics and health policy 9 (6), 389-402, 2011
232011
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
V Diaby, G Adunlin, SB Zeichner, K Avancha, G Lopes, S Gluck, ...
Breast cancer research and treatment 147 (2), 433-441, 2014
202014
Value assessment frameworks in the United States: a call for patient engagement
V Diaby, AA Ali, AJ Montero
PharmacoEconomics-Open 3 (1), 1-3, 2019
162019
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
NA Limdi, LH Cavallari, CR Lee, WB Hillegass, AM Holmes, TC Skaar, ...
The pharmacogenomics journal 20 (5), 724-735, 2020
142020
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives
V Diaby, AA Ali, KJ Williams, K Ezendu, E Soto-Perez-de-Celis, ...
Breast cancer research and treatment 166 (3), 951-963, 2017
142017
ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare
V Diaby, V Sanogo, KR Moussa
Expert review of pharmacoeconomics & outcomes research 16 (1), 141-147, 2016
142016
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
V Diaby, G Adunlin, AA Ali, R Tawk
Breast cancer research and treatment 146 (3), 669-673, 2014
122014
Timing, costs, and survival outcome of specialty palliative care in medicare beneficiaries with metastatic non–small-cell lung cancer
J Huo, YR Hong, K Turner, V Diaby, C Chen, J Bian, R Grewal, DJ Wilkie
JCO Oncology Practice 16 (12), e1532-e1542, 2020
112020
The system can't perform the operation now. Try again later.
Articles 1–20